TL;DR: ⚪ Null — neither haloperidol nor ziprasidone for ICU delirium showed any long-term (3- or 12-month) cognitive, functional, or psychological benefit to survivors.
1. Publication
- Title: Long-term outcomes after treatment of delirium during critical illness with antipsychotics (MIND-USA): a randomised, placebo-controlled, phase 3 trial
- Acronym: MIND-USA (long-term follow-up)
- Year & Journal: Lancet Respiratory Medicine, published April 30, 2024
- Citation: Mart MF, Boehm LM, Kiehl AL, et al. Lancet Respir Med. 2024. doi:10.1016/S2213-2600(24)00077-8
2. Context & Rationale
Background: The original MIND-USA trial found neither haloperidol nor ziprasidone improved short-term delirium/coma-free days in critically ill patients. Whether antipsychotics might still confer longer-term cognitive, functional, or psychological benefit in survivors remained unknown — a genuine, previously unaddressed question given post-intensive care syndrome's long natural history.
Research Question/Hypothesis: In delirious, critically ill adults treated with haloperidol, ziprasidone, or placebo, are there differences in long-term (3- and 12-month) cognitive, functional, psychological, or quality-of-life outcomes among survivors?
3. Design & Methods
- Study Type: Prespecified long-term follow-up of the randomized, double-blind, placebo-controlled phase 3 MIND-USA trial
- Setting & Centers: 16 US hospitals
- Population: Adults with respiratory failure or septic/cardiogenic shock and delirium; ~21,000 screened, >560 enrolled
- Intervention: IV haloperidol or ziprasidone, up to 14 days
- Comparator: Placebo
- Statistical Power & Follow-Up: Outcomes assessed at 3 and 12 months via standardized telephone assessments: cognitive, functional, psychological, quality-of-life, and employment metrics.
4. Key Results
Outcome | Haloperidol | Ziprasidone | Placebo | Notes |
Cognitive/functional/psychological/QoL outcomes at 3 and 12 months (primary) | No significant benefit | No significant benefit | Reference | Clear null across all three groups |
Survival and response rates | Similar | Similar | Similar | No differential survival signal |
Cognitive impairment at 3/12 months | ~1/3 of survivors affected, regardless of group | — | — | Substantial burden of impairment overall, unrelated to treatment |
Employment limitations | Over half of survivors affected, regardless of group | — | — | Substantial functional burden overall, unrelated to treatment |
5. Internal Validity Assessment
Prespecified long-term follow-up of a rigorous randomized, double-blind, placebo-controlled phase 3 trial. Overall: Strong — the paper is described as the first to demonstrate, with long-term follow-up, that neither antipsychotic significantly improves cognitive, functional, or psychological outcomes in survivors; standardized telephone assessment methodology across multiple domains adds rigor.
6. External Validity Assessment
16-hospital US ICU population with delirium and respiratory failure/shock — broadly representative of general medical/surgical ICU delirium populations.
7. Strengths & Limitations
Strengths: Long-term (12-month), multi-domain follow-up of a rigorous phase 3 trial; addresses a genuine gap (whether short-term-null drugs might still help long-term); large screening funnel supporting representativeness of the enrolled population.
Limitations: As with many long-term critical-illness follow-up studies, loss to follow-up and survivor-bias considerations are inherent challenges (addressed in an accompanying Lancet Respir Med commentary on statistical methods for functional outcomes in trials with severely ill patients).
8. Interpretation & Practice Impact
Reinforces that antipsychotics (haloperidol, ziprasidone) should not be used routinely to treat delirium in critically ill adults — not only do they fail to shorten delirium/coma-free days short-term, they also confer no long-term cognitive, functional, or psychological benefit to survivors.
9. Controversies & Subsequent Evidence
An accompanying Lancet Respir Med commentary ("Treatment effects on functional outcomes in trials with severely ill patients") specifically addresses methodological challenges (loss to follow-up, appropriate outcome measures, matching follow-up duration to long-term sequelae) relevant to interpreting this and similar long-term critical-illness trials. The findings are consistent with the related AID-ICU trial (haloperidol vs placebo, 1000 patients).
10. Summary & Executive Takeaway
Summary: This prespecified long-term follow-up of MIND-USA assessed 3- and 12-month cognitive, functional, psychological, and quality-of-life outcomes in delirious ICU survivors randomized to haloperidol, ziprasidone, or placebo. Neither antipsychotic showed significant benefit on any long-term outcome domain; roughly a third of survivors had cognitive impairment and over half had employment limitations, regardless of treatment group.
Overall Takeaway: Antipsychotics used to treat ICU delirium confer no long-term cognitive, functional, or psychological benefit to survivors, reinforcing that they should not be used routinely for this indication — while highlighting the substantial, treatment-independent long-term burden of critical illness with delirium that current pharmacotherapy does not address.
11. Bibliography
- Girard TD, Exline MC, Carson SS, et al. Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness (MIND-USA). N Engl J Med. 2018;379(26):2506-2516.
- Andersen-Ranberg NC, et al. Haloperidol for the Treatment of Delirium in ICU Patients (AID-ICU). N Engl J Med. 2022;387(26):2425-2435.
- Colantuoni E, Scharfstein DO, Wang C, et al. Statistical methods to compare functional outcomes in RCTs with high mortality. BMJ. 2018;360:j5748.